What is William Blair's Forecast for Korro Bio Q2 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities research analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for shares of Korro Bio in a report released on Thursday, May 8th. William Blair analyst M. Minter now expects that the company will post earnings of ($3.11) per share for the quarter, down from their previous forecast of ($2.98). The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio's Q3 2025 earnings at ($3.03) EPS, Q4 2025 earnings at ($3.06) EPS, FY2025 earnings at ($11.70) EPS, FY2026 earnings at ($12.66) EPS, FY2027 earnings at ($13.46) EPS, FY2028 earnings at ($12.85) EPS and FY2029 earnings at $15.22 EPS.

Several other brokerages have also recently commented on KRRO. Chardan Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Korro Bio in a research report on Tuesday. HC Wainwright lowered their price objective on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Royal Bank of Canada decreased their price target on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 19th. Cantor Fitzgerald raised shares of Korro Bio to a "strong-buy" rating in a research note on Tuesday, April 29th. Finally, Oppenheimer decreased their target price on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Korro Bio currently has an average rating of "Buy" and a consensus target price of $104.63.

Korro Bio Stock Performance

Shares of NASDAQ:KRRO traded down $1.44 during mid-day trading on Monday, hitting $14.11. 107,465 shares of the company traded hands, compared to its average volume of 98,182. The firm's 50 day simple moving average is $17.53 and its 200 day simple moving average is $33.59. The firm has a market cap of $132.51 million, a P/E ratio of -1.49 and a beta of 2.66. Korro Bio has a 52-week low of $11.13 and a 52-week high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping analysts' consensus estimates of ($2.60) by $0.11. The business had revenue of $2.55 million for the quarter, compared to analysts' expectations of $0.13 million.

Institutional Trading of Korro Bio

A number of large investors have recently added to or reduced their stakes in the company. AlphaQuest LLC increased its position in Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock worth $83,000 after acquiring an additional 412 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Korro Bio by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company's stock valued at $563,000 after purchasing an additional 435 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Korro Bio by 9.0% during the 4th quarter. Bank of America Corp DE now owns 7,037 shares of the company's stock valued at $268,000 after purchasing an additional 581 shares during the last quarter. Rhumbline Advisers boosted its position in Korro Bio by 7.8% during the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock worth $366,000 after buying an additional 691 shares during the period. Finally, Blair William & Co. IL boosted its position in Korro Bio by 5.7% during the 4th quarter. Blair William & Co. IL now owns 12,895 shares of the company's stock worth $491,000 after buying an additional 695 shares during the period. Institutional investors and hedge funds own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).